UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DC ~~20549~~D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of the Securities Exchange Act of 1934

Date of ~~the~~ ~~Securities~~Report ~~Exchange~~(Date ~~Act~~ of ~~1934~~earliest event reported): July 9, 2019

~~Date of~~Emmaus ~~report~~Life Sciences, Inc. (~~Date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):~~specified ~~July~~in 8,its ~~2019~~ charter)

Emmaus Life Sciences, Inc.

Delaware		000-53072		41-2254389
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

(Exact Name of Registrant as Specified in Its Charter)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Delaware		000-53072		41-2254389
(State or Other Jurisdiction of Incorporation		(Commission File Number)		(IRS Employer Identification No.)

Registrant’s telephone number, including area code (310) 214-0065

~~21250 Hawthorne~~(Former ~~Boulevard,~~name ~~Suite~~or ~~800~~former address, ~~Torrance~~if changed, CAsince ~~90503~~last report.)

~~(Address,~~Check the appropriate box below if the Form ~~including~~8-K ~~zip~~filing ~~code,~~is ~~off~~intended ~~principal~~to ~~executive~~simultaneously ~~offices)~~satisfy the filing obligation of the registrant under any of the following provisions:

Registrant’s telephone number, including area code 310-214-0065

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.~~14d2~~14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.~~13e~~13a-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section ~~13a~~ 13(a) of the Exchange Act. ☒ ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

~~ITEM 8~~Item 5.0107 ~~Other~~Submission ~~Events~~of Matters to a Vote of Security Holders.

On July 89, 2019, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) held ~~issued~~ a ~~press~~special ~~release~~meeting ~~related~~of tostockholders (the ~~company’s Pilot/Phase~~“Special IMeeting”). The ~~study~~principal purpose of ~~its~~the ~~pharmaceutical-grade~~Special ~~L-glutamine~~Meeting was into consider and act upon the ~~treatment~~proposal ofto ~~diverticulosis.~~adopt Aand ~~copy~~approve the Agreement and Plan of Merger and Reorganization, dated January 4, 2019, as amended from time to time (as so amended, the ~~press~~“Merger ~~releases~~Agreement”), among Emmaus, MYnd Analytics, Inc. (“MYnd”) and Athena Merger Subsidiary, Inc. “Merger Sub”), pursuant to which Merger Sub is to merge ~~included~~(the “Merger”) with and into Emmaus, with Emmaus to survive the Merger as ~~Exhibit 99~~a wholly owned subsidiary of MYnd.1 toFor more ~~this~~information ~~Current~~about ~~Report~~the purposes of the Special Meeting, see the Notice of Special Meeting of Emmaus stockholder and the section entitled “The Special Meeting of Emmaus Stockholders” in the joint proxy statement/prospectus (the “joint proxy statement/prospectus”) filed by us on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on June 14, 2019, which information is incorporated herein by reference.

~~Item 9~~The number of shares of common stock entitled to vote at the Special Meeting was 34,051,394, of which ______ shares were present or represented by proxy at the Special Meeting.01 ~~Financial~~The ~~Statements~~proposal to adopt and ~~Exhibits.~~approve the Merger Agreement and the Merger was approved by the following vote:

For				Against				Abstain				Broker Non-votes
	28,292,446				3,686				19,872				0

As the forgoing proposal was approved, we dispensed with a vote on the proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies.

Item 8.01

Other Events.

On July 10, 2019, Emmaus and MYnd issued a joint press release, a copy of which is filed as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

See the accompanying Index to Exhibits, which information is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 8, 2019	EMMAUS LIFE SCIENCES, INC.
Date: July 10, 2019	Emmaus Life Sciences, Inc.
	By:	/s/ ~~WILLIS~~YUTAKA ~~C. LEE~~NIIHARA
	Name:	Willis C. Lee
		Name: Yutaka Niihara, M.D., M.P.H.
	Title:	Chief Operating Officer
		Title: Chairman and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit Number		Description
Exhibit No.		Description of Exhibit
99.1		~~July~~Press ~~8, 2019 press~~ release of ~~Emmaus~~July ~~Life Sciences~~10, ~~Inc.~~2019

Filing Compare · EMI Holding, Inc.